Belldegrun Arie's Form 4 filing
Allogene Therapeutics, Inc. (ALLO) · filed Jan 14, 2022
- Accession no.
- 0001214659-22-000701
- Filed
- Jan 14, 2022
- Trade date
- Jan 12, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction. Open-market purchases total $1.95M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Belldegrun ArieCIK 0001296549 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 12, 2022 | Common Stock | PPurchaseAcquired | +155,039 | $12.60F1 | +$1,953,491.4 | 195,039 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The reported securities were purchased by Bellco Legacy LLC at an average price of $12.60 per unit, calculated from the price range of $12.35 to $13.00.
Referenced by the price of 1 transaction in Table I.